Načítá se...

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

INTRODUCTION: Elevated expression of erbB3 rendered erbB2-overexpressing breast cancer cells resistant to paclitaxel via PI-3 K/Akt-dependent upregulation of Survivin. It is unclear whether an erbB3-targeted therapy may abrogate erbB2-mediated paclitaxel resistance in breast cancer. Here, we study t...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wang, Shuiliang, Huang, Jingcao, Lyu, Hui, Cai, Bo, Yang, Xiaoping, Li, Fang, Tan, Jianming, Edgerton, Susan M, Thor, Ann D, Lee, Choon-Kee, Liu, Bolin
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3978722/
https://ncbi.nlm.nih.gov/pubmed/24168763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3563
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!